MEDRAD, Inc.：市場シェア分析...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 What Is This Report About? 7
3 Definitions of Markets/Categories Covered 8
3.1 Diagnostic Imaging 8
3.1.1 Contrast Media Injectors 8
4 Company Snapshot 9
4.1 Key Information 9
4.2 Company Overview 9
4.3 Major Products and Services 10
4.3.1 Overview 10
5 Competitors 13
6 Competitive Landscape 14
6.1 Diagnostic Imaging (Contrast Media Injectors), Global, Market Share (%), 2011 14
6.2 MEDRAD, Inc., Diagnostic Imaging (Contrast Media Injectors), by Region, Market Share (2011) 16
6.3 MEDRAD, Inc., Diagnostic Imaging (Contrast Media Injectors), by Country, Market Share (2011) 17
7 Key Employees 19
8 Locations And Subsidiaries 20
8.1 Head Office 20
8.2 Other Locations & Subsidiaries 20
9 Financial Deals Landscape 22
9.1 MEDRAD, INC., Deals Volume Summary, 2007 to 2012 22
10 MEDRAD, INC. Detailed Deal Summary 24
10.1 Venture Financing 24
10.1.1 Pathway Medical Technologies Secures $9.9 Million In Financing Round 24
10.1.2 Pathway Medical Technologies Secures $42.5 Million In Series D Financing 25
10.1.3 Pathway Medical Technologies Secures $24.5 Million In Series C Round Of Financing 27
10.2 Partnerships 29
10.2.1 MEDRAD Enters Into Licensing Agreement With B. Braun Melsungen 29
10.2.2 MEDRAD Enters Into A Distribution Agreement With WFR-AQUAPLAST And Qfix Systems 30
10.2.3 Merge Healthcare Expands European Distribution Agreement With MEDRAD 31
10.2.4 MEDRAD Enters Into Research Agreement With The University of South Florida And Moffitt Cancer Center 32
10.2.5 MEDRAD Signs Research Agreement With University of Zurich 33
10.2.6 Confirma Signs An Agreement With MEDRAD 34
10.2.7 MEDRAD Enters Into A Distribution Agreement With PETNET Solutions 35
10.2.8 MEDRAD Signs An Agreement With Abbott Point of Care 36
10.3 Acquisition 37
10.3.1 MEDRAD Completes Acquisition Of Pathway Medical Technologies For $125 Million 37
10.3.2 MEDRAD Completes Acquisition Of Possis Medical 39
11 Recent Developments 41
11.1 Strategy And Business Planning 41
11.1.1 Mar 01, 2012: Bayer HealthCare Forms New Business Unit, Announces Integration Of Contrast Media, Injector And Interventional Businesses 41
11.1.2 Mar 24, 2010: MEDRAD MVS Opens New Ultrasound Probe Repair Facility In Denver 41
11.2 Financial Announcements 42
11.2.1 Mar 26, 2009: MEDRAD Revenues Grow 10% In 2008 42
11.2.2 Mar 04, 2008: MEDRAD Declares 2007 Results 43
11.3 Research And Development 44
11.3.1 Aug 22, 2009: MEDRAD Signs PET Research Agreement With USF 44
11.3.2 Jan 06, 2009: MEDRAD Signs PET Research Agreement With University Of Zurich 45
11.4 Corporate Communications 46
11.4.1 Jan 05, 2011: MEDRAD Lays Off Workforce 46
11.4.2 May 11, 2010: MEDRAD Appoints Samuel Liang As President, CEO 46
11.5 Product News 47
11.5.1 Jun 20, 2012: Bayer Launches Medrad Mark 7 Arterion Injection System 47
11.5.2 Nov 10, 2011: Bayer HealthCare’s Cotavance Drug Eluting Balloon With Paccocath Technology Reduced Five-Year Target Lesion Revascularization Rates By 59% In PAD Patients Compared To Those Treated With Uncoated Balloon 47
11.5.3 Nov 03, 2011: MEDRAD Announces Five-Year Data Of Cotavance Drug Eluting Balloon With Paccocath Technology To Be Presented At 2011 TCT 48
11.5.4 Sep 15, 2011: Medrad Enrolls First Patient In EURO CANAL Study To Evaluate Cotavance Paclitaxel Eluting Balloon With Paccocath Technology In Treating Critical Leg Ischemia Below Knee 49
11.5.5 Sep 12, 2011: Medrad Receives CE Mark For Next Generation Cotavance Paclitaxel Coated Balloon Angioplasty Catheter With Paccocath Technology 50
11.5.6 May 16, 2011: Medrad Announces European Approval And Launch Of Cotavance Drug Eluting Balloon With Paccocath Technology 51
11.5.7 Jan 06, 2009: PET Research At University Of Zurich Is Sponsorsed By MEDRAD 52
11.5.8 Aug 11, 2008: MEDRAD Receives FDA 510(k) Clearance For Wireless MR Infusion System 52
11.5.9 Aug 07, 2008: MEDRAD Installs First Intego PET Infusion System 53
11.5.10 Jun 17, 2008: MEDRAD Receives FDA 510(k) Clearance For FDG Infusion System 53
11.5.11 May 22, 2008: MEDRAD XDS Extravasation Detector Wins Medical Design Excellence Award 54
11.6 Product Approvals 55
11.6.1 Sep 12, 2011: Medrad Receives CE Mark For Next Generation Cotavance Paclitaxel Coated Balloon Angioplasty Catheter With Paccocath Technology 55
11.6.2 May 16, 2011: Medrad Announces European Approval And Launch Of Cotavance Drug Eluting Balloon With Paccocath Technology 56
11.6.3 Aug 11, 2008: MEDRAD Receives FDA 510(k) Clearance For Wireless MR Infusion System 57
11.6.4 Jun 17, 2008: MEDRAD Receives FDA 510(k) Clearance For FDG Infusion System 57
11.7 Clinical Trials 58
11.7.1 Nov 10, 2011: Bayer HealthCare’s Cotavance Drug Eluting Balloon With Paccocath Technology Reduced Five-Year Target Lesion Revascularization Rates By 59% In PAD Patients Compared To Those Treated With Uncoated Balloon 58
11.7.2 Sep 15, 2011: Medrad Enrolls First Patient In EURO CANAL Study To Evaluate Cotavance Paclitaxel Eluting Balloon With Paccocath Technology In Treating Critical Leg Ischemia Below Knee 59
11.7.3 Jan 06, 2009: PET Research At University Of Zurich Is Sponsorsed By MEDRAD 60
11.8 Other Significant Developments 61
11.8.1 Jan 27, 2012: Hospitals, Healthcare Providers To Benefit From New Premier Agreements For Contrast Media 61
11.8.2 Jan 02, 2012: Hospitals, Healthcare Providers To Benefit From New Premier Agreements For MRI Compatible Equipment 61
11.8.3 Apr 08, 2010: MEDRAD Signs Supply Agreement With ev3 For Definitive AR Pilot Study 61
11.8.4 Oct 30, 2009: Merge Healthcare, MEDRAD Expand European Union Distribution Agreement 62
12 Appendix 63
12.1 Research Methodology 64
12.2 Secondary Research 64
12.3 Primary Research 64
12.4 Models 65
12.5 Forecasts 65
12.6 Expert Panels 65
12.7 GlobalData Consulting 65
12.8 Currency Conversion 66
12.9 Contact Us 67
12.10 Disclaimer 67